GMP AAV Manufacturing
Pharmaron’s Gene Therapy CDMO, located in Liverpool, UK, leverages its industry-leading expertise in process R&D, cGMP manufacturing and advanced analytical capabilities to support our partners in the development and manufacturing of gene therapies. Our world-class, cGMP manufacturing facility is purpose-designed for viral vector manufacture. Our experience coupled with state-of-the-art analytical and manufacturing technologies ensures we design, develop and deliver high quality, approvable gene therapies.
View as PDF: GMP AAV Manufacturing
Download Poster - Downstream Purification: A Toolbox Approach for Adaptive Multi Serotype AAV Solutions
Services
- Targeted process development using best-in-class analytics to drive scale-up to cGMP
- Single-use technology
- Suspension-based cell culture
- Serotype dependent toolbox approach to downstream
processing
- Chromatography-based purification solutions
- Automated and high-throughput development platforms
- Starting material production, management and release
- Phase-appropriate method validation and method transfer
- Advanced analytical toolkit for process & product characterisation
- Rapid transition from development to clinical manufacture, utilising Pharmaron’s established platform processes and multi-skilled process sciences team
- Effective scale-up and technical transfer to one of our GMP viral vector suites
- Quality assurance and qualified person batch release
- On-site cryo storage
Capabilities
- Scalable suspension culture systems
- Range of GMP bioreactor scales (50L to 500L)
- Single-use technologies
- Chromatography-based purification
- Purification by ultracentrifugation available
- Comprehensive analytical toolkit
- Unique viral vector characterisation analytics
- Dedicated QC analytical capabilities
Learn more about Pharmaron’s expertise by registering for our monthly CGT webinar series, which is focused on identifying key cell and gene therapy questions that arise during drug discovery and development. Register here.
